AbbVie selects Durham, North Carolina for its largest ever manufacturing campus

AbbVie has announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, marking the company’s largest single capital investment since its founding. Construction begins this year, with completion expected by end of 2028.

The campus, located near Research Triangle Park, will support production of AbbVie’s immunology, neuroscience and oncology medicines, integrating advanced manufacturing and laboratory technologies with artificial intelligence. The first phase will focus on small volume parenteral drug product manufacturing, which covers sterile injectable medicines including vials, prefilled cartridges and syringes. When complete, the site will serve as AbbVie’s U.S. centre of excellence for that manufacturing category.

The project will create 734 permanent jobs over four years, spanning engineers, scientists, manufacturing operators and laboratory technicians, alongside more than 2,000 construction jobs during the build phase.

Robert Michael, AbbVie’s chairman and chief executive, framed the investment as both a strategic and community commitment: “By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”

North Carolina Governor Josh Stein welcomed the announcement: “When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business.”

The Durham campus forms part of AbbVie’s broader $100 billion commitment to U.S. research, development and manufacturing over the next decade. The company says it has now committed more than $2.2 billion in U.S. manufacturing investment over the past 12 months alone, creating over 1,300 jobs across North Carolina, Illinois, Arizona and Massachusetts.

---

---

Related Topics and Keywords

AbbVie, AbbVie Inc